MedTrace Logo

Short-term Impact of Cyplexinol® on Self-reported Joint Pain

NCT04764110 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-08-22

No results posted yet for this study

Summary

In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15 days in comparison with a placebo will be determined using a cross-over double blind design with a 13 day wash out period. In addition, we will measure cytokine production and related variables during the two hour after subjects ingest a single dosage of Cyplexinol® or placebo on days 1 and 15.

Conditions

Interventions

DIETARY_SUPPLEMENT

Cyplexinol

partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)

OTHER

Placebo

Maltodextrin

Sponsors & Collaborators

  • ZyCal Bioceuticals

    collaborator UNKNOWN

  • University of Memphis

    lead OTHER

Principal Investigators

  • Richard Bloomer, PhD · University of Memphis

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2022-01-28
Completion
2022-01-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04764110 on ClinicalTrials.gov